AKTX

Akari Therapeutics Plc

11.54 USD

Last updated Sep 5, 11:36 UTC

Yesterday HIGH

$11.8

Yesterday LOW

$10.17

52w HIGH

$49.6

52w LOW

$3.02

EPS

0.00

PE

0.00

Next Earnings

Nov 12, 2026

Overview News Insider Transactions Government Trades Fundamentals

Akari Therapeutics Plc stock is up 42.82% since 30 days ago. The next earnings date is Nov 12, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 11 September’s closed higher than August.

Benzinga Insights

Fri May 22, 2026

12 Health Care Stocks Moving In Friday's Intraday Session
Avi Kapoor

Fri May 22, 2026

Crude Oil Edges Higher; US Consumer Sentiment Falls In May

US stocks rose, Dow gained over 400 points. S&P 500 and NASDAQ also up. Health care shares jumped, while communication services fell. University of Michigan's consumer sentiment index hit record low. Oil up, gold and silver down. European and Asian markets closed higher.
Evette Mitkov

Fri May 22, 2026

Akari Therapeutics Stock Jumps On Promising Preclinical Data

Akari Therapeutics shares are surging after preclinical data showed AKTX‑101 synergized with KRAS inhibition in pancreatic cancer models.
Avi Kapoor

Fri May 22, 2026

Dow Jumps 250 Points; BJ's Wholesale Shares Fall After Q1 Results

US stocks rise with the Dow gaining 250 points. Health care shares jump while energy stocks fall. BJ's Wholesale Club stock falls 7% after earnings.
Avi Kapoor

Fri May 22, 2026

Why Estee Lauder Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket

Estee Lauder (EL) shares jumped 11.8% in pre-market trading after ending discussions with Puig. Other gainers include PCLA, AKTX, LFS, BIYA, QTEX, GOVX, COHN, SQNS, and IMAX.
Benzinga Newsdesk

Fri May 22, 2026

Akari Therapeutics shares are trading higher after the company announced preclinical data demonstrating synergistic activity of AKTX-101 with KRAS inhibition in KRAS-mutated pancreatic cancer models
Benzinga Insights

Fri May 22, 2026

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights

Thu May 21, 2026

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Newsdesk

Thu May 21, 2026

Akari Therapeutics' AKTX-101 Shows Synergistic Preclinical Cytotoxicity With KRAS Inhibitor In KRAS-Mutant Pancreatic Cancer Models, Highlighting RNA Splicing Payload Advantage

An ADC with a novel RNA spliceosome modulating payload PH1 paired with a KRAS inhibitor demonstrates synergistic cytotoxic activity against KRAS G12D and G12C- driven pancreatic cancer modelsData supports the broader
Benzinga Newsdesk

Thu May 21, 2026

Akari Therapeutics shares are trading higher after the company announced a $5 million private placement.

Kameel Farag, Interim CFO

Mon Aug 17, 2026

AKTX Recent Insider Trades and Stock Chart

1,728 shares awarded
Kameel Farag, Interim CFO

Thu Jul 16, 2026

AKTX Recent Insider Trades and Stock Chart

1,130 shares awarded